

Case Report

A case of spotted fever rickettsiosis in a human immunodeficiency virus-positive patient

Claudia Colomba, Lucia Siracusa, Simona Madonia, Laura Saporito, Celestino Bonura, Simona De Grazia and Giovanni M. Giammanco

Correspondence

Laura Saporito
laura.sapo@tin.it

Received 9 October 2012

Accepted 19 June 2013

Università degli studi di Palermo, Palermo, Italy

Introduction

Mediterranean spotted fever (MSF) due to *Rickettsia conorii* is an acute febrile disease endemic in Italy, where about 400 cases are reported every year, transmitted to humans by the brown dog tick. Nearly half of Italian MSF cases occur in Sicily (Colomba *et al.*, 2006). However, in recent years other tick-borne spotted fever group rickettsiae such as *Rickettsia conorii israelensis*, *Rickettsia conorii caspia*, *Rickettsia slovaca*, *Rickettsia massiliae*, *Rickettsia aeschlimannii*, *Rickettsia akari* and *Rickettsia sibirica mongolitimonae* have been documented to cause infection in humans in the Mediterranean basin. All of these agents, although causing milder illnesses than *R. conorii*, cross-react with *R. conorii*, thus requiring care in interpretation of serological tests. MSF in an immunocompetent host is typically characterized by fever, skin rash and a black eschar at the site of the tick bite ('tache noire'). Here, we describe a case of spotted fever rickettsiosis with a benign course in a human immunodeficiency virus-positive patient.

Case report

A 49-year-old Italian male with longstanding human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection was admitted to the Infectious Disease Unit of the University Hospital of Palermo, Palermo, Italy, in May 2012 with a 5-day history of continuous remittent fever, severe headache and arthromyalgia, and with skin rash presenting 24 h before admission.

At the time of admission, he was taking darunavir, ritonavir, raltegravir and etravirine. His most recent HIV RNA viral load was undetectable and his CD4⁺ cell count was 235 µl⁻¹ (16.64%). His plasma HCV RNA level was 2 370 000 IU l⁻¹. His body temperature was 38 °C, blood pressure 140/90 mmHg and heart rate 94 beats min⁻¹. Physical examination showed hepatomegaly and a maculopapular skin rash over his whole body but especially on the palms, and some of these lesions were petechial; an

eschar was detected on his right leg. No tick was found. An electrocardiogram and chest X-ray were normal. Laboratory examination demonstrated normal white and red blood cell counts and a normal haemoglobin value, with a low platelet count (91 000 cells ml⁻¹); serum creatinine was in the normal range (0.73 mg dl⁻¹), aspartate aminotransferase was 54 U l⁻¹, alanine aminotransferase was 51 U l⁻¹ and lactate dehydrogenase was 605 IU l⁻¹. C-reactive protein was 26.77 mg dl⁻¹. Coagulation parameters were within normal limits.

Clinical diagnosis of MSF was made, and the patient started therapy with oral doxycycline (100 mg twice daily) from the day of admission for 10 days. The patient improved within 72 h, and 6 days after admission had recovered completely. A *Rickettsia conorii* serological test performed on day 2 was negative, but rickettsial DNA was detected from both full blood and buffy coat samples with a highly sensitive real-time PCR assay for the detection of spotted fever and typhus group rickettsiae (Stenos *et al.*, 2005). An immunofluorescent antibody test for *R. conorii* performed after a 2-week interval showed both IgM (1:320) and IgG (1:1280).

Discussion

MSF is a benign disease in children, while severe complications can arise in adults (Colomba *et al.*, 2006, 2008; Giammanco *et al.*, 2005; Saporito *et al.*, 2010). Diagnosis is based on epidemiological, clinical and laboratory criteria. The mortality rate of MSF is usually estimated at around 2.5% and risk factors for severe forms include elderly patients, diabetes, cardiovascular illness, chronic renal failure, glucose 6-phosphate dehydrogenase deficiency and chronic alcoholism (Brouqui *et al.*, 2007; Schmulewitz *et al.*, 2008; Sousa *et al.*, 2008). Complicated forms of the disease have also been described in patients without risk factors (Colomba *et al.*, 2008, 2011; Giammanco *et al.*, 2005; Saporito *et al.*, 2010). A single case of MSF was described in an immunocompromised patient after liver transplantation and the illness was lethal

Abbreviations: HCV, hepatitis C virus; HIV, human immunodeficiency virus; MSF, Mediterranean spotted fever; SFG, spotted fever group.

(Barrio *et al.*, 2002). Sometimes primary HIV infection can mimic MSF presentation (Segura *et al.*, 2002).

Our patient exhibited a typical MSF clinical picture, including a maculopapular rash and a black eschar at the site of the tick bite. In Sicily, *R. conorii* is the most common agent of MSF (Giammanco *et al.*, 2005), but other spotted fever group (SFG) rickettsiae cannot be excluded to have caused the infection, as no sufficiently long PCR product could be used for sequencing and serological tests for *R. conorii* cannot exclude cross-reactions with other SFG rickettsiae. The course and outcome of the disease were favourable. Although the agent responsible for the illness was not identified precisely, this case could either be a milder-than-expected MSF or a severe clinical picture caused by a less pathogenic SFG rickettsia.

The immune mechanisms by which the host controls rickettsial infection are highly dependent on cellular immunity, with a critical role identified for CD4⁺ and CD8⁺ T lymphocytes. T lymphocytes are a potentially rich source of gamma interferon, which plays an important role in controlling spotted fever rickettsiosis by activating endothelial cells, the major target cells of rickettsial infections, to kill intracellular organisms (Barrio *et al.*, 2002). However, in mice, depletion of CD4⁺ cells has no observed effect on the course or outcome of infection (Mansueto *et al.*, 2012). In contrast, CD8⁺-depleted mice, infected with sublethal doses of *R. conorii*, remain persistently infected and ill, and a high proportion of these animals die of uncontrolled rickettsial infection (Walker *et al.*, 2001).

In our case, the CD4⁺ T-lymphocytes count was not strikingly low and apparently did not play a crucial role in worsening the prognosis of the disease. Possibly, the awareness of the disease in this endemic area, its prompt recognition and timely antibiotic administration may have shortened the symptomatic period and prevented the appearance of severe complications of MSF in our immunocompromised patient. However, whether or not a less pathogenic SFG agent was involved, the presence of petechiae and significant thrombocytopenia would indicate that HIV-positive patients could be prone to develop more severe presentations than expected. In both cases, routine use of molecular biology tools might shorten the time to laboratory diagnosis and allow administration of treatment without delay.

References

- Barrio, J., de Diego, A., Ripoll, C., Perez-Calle, J. L., Núñez, O., Salcedo, M. & Clemente, G. (2002). Mediterranean spotted fever in liver transplantation: a case report. *Transplant Proc* **34**, 1255–1256.
- Brouqui, P., Parola, P., Fournier, P. E. & Raoult, D. (2007). Spotted fever rickettsioses in southern and eastern Europe. *FEMS Immunol Med Microbiol* **49**, 2–12.
- Colomba, C., Saporito, L., Polara, V. F., Rubino, R. & Titone, L. (2006). Mediterranean spotted fever: clinical and laboratory characteristics of 415 Sicilian children. *BMC Infect Dis* **6**, 60.
- Colomba, C., Saporito, L., Colletti, P., Mazzola, G., Rubino, R., Pampinella, D. & Titone, L. (2008). Atrial fibrillation in Mediterranean spotted fever. *J Med Microbiol* **57**, 1424–1426.
- Colomba, C., Saporito, L., Siracusa, L., Giammanco, G., Bonura, S. & Titone, L. (2011). [Mediterranean spotted fever in paediatric and adult patients: two clinical aspects of the same disease]. *Infez Med* **19**, 248–253 (in Italian).
- Giammanco, G. M., Vitale, G., Mansueto, S., Capra, G., Caleca, M. P. & Ammatuna, P. (2005). Presence of *Rickettsia conorii* subsp. *israelensis*, the causative agent of Israeli spotted fever, in Sicily, Italy, ascertained in a retrospective study. *J Clin Microbiol* **43**, 6027–6031.
- Mansueto, P., Vitale, G., Cascio, A., Seidita, A., Pepe, I., Carroccio, A., di Rosa, S., Rini, G. B., Cillari, E. & Walker, D. H. (2012). New insight into immunity and immunopathology of rickettsial diseases. *Clin Dev Immunol* **2012**, 967852.
- Saporito, L., Giammanco, G. M., Rubino, R., Ingrassia, D., Spicola, D., Titone, L. & Colomba, C. (2010). Severe Mediterranean spotted fever complicated by acute renal failure and herpetic oesophagitis. *J Med Microbiol* **59**, 990–992.
- Schmulewitz, L., Moumile, K., Patey-Mariaud de Serre, N., Poirée, S., Gouin, E., Mechaï, F., Coccard, V., Mamzer-Bruneel, M. F., Abachin, E. & other authors (2008). Splenic rupture and malignant Mediterranean spotted fever. *Emerg Infect Dis* **14**, 995–997.
- Segura, F., Antón, E., Font, B., Sala, M. & Cervantes, M. (2002). Primary HIV type-1 infection misdiagnosed as Mediterranean spotted fever. *Eur J Clin Microbiol Infect Dis* **21**, 478–479.
- Sousa, R., França, A., Dória Nóbrega, S., Belo, A., Amaro, M., Abreu, T., Poças, J., Proença, P., Vaz, J. & other authors (2008). Host- and microbe-related risk factors for and pathophysiology of fatal *Rickettsia conorii* infection in Portuguese patients. *J Infect Dis* **198**, 576–585.
- Stenos, J., Graves, S. R. & Unsworth, N. B. (2005). A highly sensitive and specific real-time PCR assay for the detection of spotted fever and typhus group Rickettsiae. *Am J Trop Med Hyg* **73**, 1083–1085.
- Walker, D. H., Olano, J. P. & Feng, H. M. (2001). Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection. *Infect Immun* **69**, 1841–1846.